Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey R Oxnard

Showing results (61-70 of 199) with videos related to

Pageof 20
Sort By:
The Oncologist|September 7, 2022
Real-World Comprehensive Genomic Profiling Success Rates in Tissue and Liquid Prostate Carcinoma SpecimensMatthew C Hiemenz, Ryon P Graf, Kelsie Schiavone, et al.
Oncology and Therapy|July 24, 2020
Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access ProgramEdgardo S Santos, Barry Kaplan, Eli Kirshner, et al.
Journal for Immunotherapy of Cancer|October 27, 2022
Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor typesJake G Maule, Lani K Clinton, Ryon P Graf, et al.
Journal of the National Cancer Institute|August 10, 2014
Realizing the potential of plasma genotyping in an age of genotype-directed therapiesJason J Luke, Geoffrey R Oxnard, Cloud P Paweletz, et al.
Journal of the National Cancer Institute|August 29, 2012
When progressive disease does not mean treatment failure: reconsidering the criteria for progressionGeoffrey R Oxnard, Michael J Morris, F Stephen Hodi, et al.
Cancer Research Communications|March 16, 2023
Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal CancerRyon P Graf, Virginia Fisher, James Creeden, et al.
Neuro-Oncology|August 26, 2011
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancerChristian Grommes, Geoffrey R Oxnard, Mark G Kris, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNAJulianna G Supplee, Marina S D Milan, Lee P Lim, et al.
Clinical Lung Cancer|June 5, 2018
Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid TumorsD Ross Camidge, Lecia V Sequist, Pasi A Jänne, et al.
JCO Precision Oncology|March 7, 2024
Association of Timely Comprehensive Genomic Profiling With Precision Oncology Treatment Use and Patient Outcomes in Advanced Non-Small-Cell Lung CancerJeff Yorio, Katherine T Lofgren, Jessica K Lee, et al.
Pageof 20

Showing results (61-70 of 199) with videos related to

Sort By:
Pageof 20
The Oncologist|September 7, 2022
Real-World Comprehensive Genomic Profiling Success Rates in Tissue and Liquid Prostate Carcinoma SpecimensMatthew C Hiemenz, Ryon P Graf, Kelsie Schiavone, et al.
Oncology and Therapy|July 24, 2020
Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access ProgramEdgardo S Santos, Barry Kaplan, Eli Kirshner, et al.
Journal for Immunotherapy of Cancer|October 27, 2022
Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor typesJake G Maule, Lani K Clinton, Ryon P Graf, et al.
Journal of the National Cancer Institute|August 10, 2014
Realizing the potential of plasma genotyping in an age of genotype-directed therapiesJason J Luke, Geoffrey R Oxnard, Cloud P Paweletz, et al.
Journal of the National Cancer Institute|August 29, 2012
When progressive disease does not mean treatment failure: reconsidering the criteria for progressionGeoffrey R Oxnard, Michael J Morris, F Stephen Hodi, et al.
Cancer Research Communications|March 16, 2023
Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal CancerRyon P Graf, Virginia Fisher, James Creeden, et al.
Neuro-Oncology|August 26, 2011
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancerChristian Grommes, Geoffrey R Oxnard, Mark G Kris, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNAJulianna G Supplee, Marina S D Milan, Lee P Lim, et al.
Clinical Lung Cancer|June 5, 2018
Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid TumorsD Ross Camidge, Lecia V Sequist, Pasi A Jänne, et al.
JCO Precision Oncology|March 7, 2024
Association of Timely Comprehensive Genomic Profiling With Precision Oncology Treatment Use and Patient Outcomes in Advanced Non-Small-Cell Lung CancerJeff Yorio, Katherine T Lofgren, Jessica K Lee, et al.
Pageof 20